TLC Evacet Cardiotoxicity Advantage Does Not Outweigh Unclear Efficacy
Executive Summary
The Liposome Company's Evacet (liposomal doxorubicin, TLC D-99) has a cardiotoxicity advantage over conventional doxorubicin when used first-line for metastatic breast cancer, the Oncologic Drugs Advisory Committee agreed Sept. 16.
You may also be interested in...
FDA Urgency To Clear TLC Evacet May Be Lessened By Ellence Approval
The impetus for FDA to approve The Liposome Company's Evacet (liposomal doxorubicin, D-99), based on incomplete efficacy data may be lessened by the recent U.S. approval of Pharmacia & Upjohn's Ellence (epirubicin).
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011